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Abstract: Mitochondrial dysfunction is emerging as an important contributory factor to the 
pathophysiology of lysosomal storage disorders (LSDs). The cause of mitochondrial dysfunction in 
LSDs appears to be multifactorial, although impaired mitophagy and oxidative stress appear to be 
common inhibitory mechanisms shared amongst these heterogeneous disorders. Once impaired, 
dysfunctional mitochondria may impact upon the function of the lysosome by the generation of 
reactive oxygen species as well as depriving the lysosome of ATP which is required by the V-ATPase 
proton pump to maintain the acidity of the lumen. Given the reported evidence of mitochondrial 
dysfunction in LSDs together with the important symbiotic relationship between these two organelles, 
therapeutic strategies targeting both lysosome and mitochondrial dysfunction may be an important 
consideration in the treatment of LSDs. In this review we examine the putative mechanisms that may 
be responsible for mitochondrial dysfunction in reported LSDs which will be supplemented with 
morphological and clinical information.  
Keywords: mitochondrial dysfunction; lysosomal storage diseases; oxidative stress; inflammation; 
reactive oxygen species; autophagy; mitophagy and cytokine 
 
1. Introduction 
Lysosomal storage diseases (LSDs) consist of a group of more than 70 inherited metabolic 
conditions caused by defects in genes that encode proteins involved in lysosomal homeostasis 
including lysosomal enzymes, non-enzymatic membrane proteins or non-lysosomal proteins [1]. The 
majority of LSDs are caused by impairment of the lysosomal acidic hydrolases, although, defective 
membrane trafficking and catabolite export together with impaired lysosome biogenesis can also cause 
a storage disorder [2]. The impairment of lysosomal function as a result of these aberrant proteins can 
lead to the accumulation of storage material(s) in endosomes and lysosomes, eventually compromising 
cellular functions [2]. The combined incidence of LSDs has been estimated to be approximately 1:5000 
live births, although the true incidence is probably underestimated [1]. 
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LSDs are disorders with autosomal recessive mode of inheritance while Fabry disease (FD), Danon 
disease, and Hunter syndrome have an X-linked inheritance pattern [3]. The age of onset and clinical 
symptoms vary for the different LSDs, although, neurological impairment is commonly associated with 
these disorders [4]. Together with LSDs, neurological dysfunction is also a common clinical 
manifestation of primary mitochondrial disease suggesting a connection between the function of these 
two organelles [5]. Lysosomes play a central role in a process known as autophagy. Autophagy is an 
intracellular mechanism by which macromolecules and organelles are transported to lysosome for 
degradation and recycling [6]. The autophagic degradation of mitochondria is known as mitophagy. 
This process enables the removal of dysfunctional mitochondria from the cell [5]. Mitophagy is 
important in post-mitotic cells such as neurons, which have limited capacity to up-regulate glycolytic 
ATP production. The removal of damaged mitochondria prevents the accumulation of reactive oxygen 
species (ROS) that are an inevitable consequence of impaired oxidative phosphorylation and may cause 
further impairment of mitochondria compromising cellular energy status [5]. Evidence of impaired 
mitophagy together with mitochondrial dysfunction has been reported in neural cells derived from a 
mouse model of Gaucher disease [7–9]. 
The acidic environment of the lysosomal lumen (pH from 5.2 to 6.1) is maintained predominantly 
by a V-ATPase. The enzyme uses the free energy liberated from the hydrolysis of ATP to pump protons 
into the lumen of the organelle [10]. Therefore, lysosomal acidification requires functioning 
mitochondria to provide the requisite ATP for this process, although no studies as far as the authors 
are aware have reported lysosomal dysfunction in patients with primary mitochondrial defects. 
However, a deficiency in the mitochondrial respiratory chain (MRC) electron carrier, coenzyme Q10 
(CoQ10) has been reported in Mucopolysaccharidosis (MPS) patients [11]. In addition to impairing 
oxidative phosphorylation and depriving the V-ATPase of a source of ATP, a deficit in CoQ10 may also 
compromise the function of the lysosomal respiratory chain that is also required for maintaining the 
acidity of this organelle [10]. In the lysosomal respiratory chain CoQ10 functions as both an electron 
and proton carrier [10]. In view of the reported susceptibility of the lysosome to oxidative stress (OS) 
induced impairment, the antioxidant function of CoQ10 may also offer some protection to this organelle 
from free radical induced oxidation [10,11]. 
In view of the important relationship between the two organelles, therapeutic strategies that target 
mitochondrial dysfunction and/or aberrant mitophagy in LSDs may be important to consider in future 
treatment modalities. 
The purpose of this review is to highlight evidence of mitochondrial dysfunction in LSDs and, 
highlight putative mechanisms and potential therapeutic strategies. In addition, case reports of patients 
with the LSDs, FD, and Pompe disease (PD) will be used to outline morphological and clinical evidence 
of mitochondrial dysfunction in these disorders. 
2. LSDs Associated with Integral Lysosomal Membrane Proteins 
Niemann Pick C 
Niemann Pick C (NPC) (OMIM #257220) is a slowly progressive neurodegenerative condition 
caused by faulty cholesterol trafficking resulting from mutations in NPC1 or NPC2 genes [12]. The 
NPC1 or NPC2 genes encode for the NPC1 membrane spanning protein and the NPC2 soluble lumen 
protein, respectively. The proteins are involved in cholesterol efflux from late endosomes and lysosome 
[12]. Mitochondrial dysfunction has been associated with NPC, although the actual cause of this 
impairment has yet to be fully elucidated and it may result from a number of different factors including 
oxidative stress and antioxidant capacity [13], increased mitochondrial cholesterol accumulation and a 
repression of mitochondrial biogenesis [14]. 
Evidence of oxidative stress (OS) in NPC has been indicated by increased levels of the oxidative 
stress marker, protein carbonyls in the livers of a mouse model of the disease (NPC mice) coupled with 
a decreased level of the cellular antioxidant, glutathione (GSH; [14]).  
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Increased levels of circulatory cholesterol oxidation products were also reported in NPC patients 
together with decreased plasma CoQ10 [15]. CoQ10 serves as an electron carrier in the MRC and also 
functions as an important lipid soluble antioxidant. A deficit of CoQ10 in NPC patients may therefore 
compromise their cellular antioxidant capacity [16]. A subsequent study Ribas et al. [17] detected 
elevated levels of lipid oxidation products (TBARS) and protein carbonyls in the plasma and fibroblasts 
from NPC patients.  
Interestingly, elevated levels of α-tocopherol, the active antioxidant form of vitamin E were 
reported in the cerebellum and cortex of mouse models of NPC, although plasma levels of α-tocopherol 
in both mice and NPC patients were comparable to control levels [18]. It was suggested that this excess 
of cellular α-tocopherol might have a pro-oxidant effect and be a contributory factor to the OS 
associated with this disorder [14]. However, studies in NPC-affected fibroblasts and hepatocytes 
indicated that α-tocopherol appears to be sequestered in vesicles of lysosomal origin and therefore it is 
not available to contribute to the cellular antioxidant capacity [18]. A deficit in peroxisomal catalase 
activity (enzyme involved in the breakdown of the ROS, hydrogen peroxide into water and oxygen) 
was reported in the brain and liver of NPC mice together with a partial impairment of fatty acid β-
oxidation capacity [19]. Peroxisomal impairment can precede clinical symptoms in mice suggesting that 
it may be a contributory factor to disease pathophysiology [19]. The defect in catalase activity may 
result from impairment in peroxisomal activation, although a deficiency in the activity of this enzyme 
has not been reported in NPC patients [17]. 
OS induced mitochondrial impairment as the result of oxidative stress exposure may be caused by 
oxidative damage to membrane phospholipids, enzymes and/or mitochondrial DNA [13]. Once 
impaired, MRC may also become a major site of ROS generation and contribute to oxidative stress 
induced cellular dysfunction [13].  
In addition to oxidative stress, mitochondrial impairment in NPC has also been associated with an 
increase in the cholesterol content of the membranes of this organelle [20]. The study by Yu et al. [21] 
demonstrated a significantly increased level of cholesterol in the mitochondrial membranes of cortical 
neurons, astrocytes, and mitochondrial derived from the brains of NPC mice which was associated with 
decreased ATP synthase activity and cellular ATP levels. The relationship between mitochondrial 
cholesterol content and oxidative phosphorylation was further supported by the ability of the 
cholesterol chelator, methyl-cyclodextrin, to restore ATP synthesis in the NPC mouse brain 
mitochondria [21]. The increase in cholesterol content is thought to adversely alter the physical 
properties of the mitochondrial membrane reducing the proton motive force and membrane potential 
with a concomitant decrease in ATP synthetic capacity [21]. An altered mitochondrial membrane lipid 
composition was shown to be associated with impaired MRC function in Parkinson`s disease as the 
possible result of aberrant super-complex formation [22]. The accumulation of cholesterol in 
mitochondrial membranes was reported to impair the transport of GSH into mitochondria, as the 
transport of this tripeptide is carrier mediated and dependent on the inner membrane fluidity [23]. 
Indeed, decreased mitochondrial GSH status was reported in the brain and liver of NPC increasing the 
vulnerability of the MRC to OS induced dysfunction [24]. Cholesterol transport from the late 
endosome/lysosome to the mitochondrion appears to be independent of the NCP1 protein and 
mediated by the cholesterol-binding membrane protein, MLN64 whose expression was reported to be 
increased in NPC1 deficient cell lines [25]. Furthermore, an overexpression of MLN64 was found to 
increase mitochondrial cholesterol content and decrease the GSH content of the organelle as well as 
impairing its function [25].  
Studies in fibroblasts derived from NPC patients and brain and liver tissue from NPC mice have 
shown that the transcription factors, KLF2 and ETV1 which repress the genes encoding mitochondrial 
proteins are up-regulated resulting in an inhibition of mitochondrial biogenesis [26]. Although the 
mechanism of action of KLF2 and ETV1 has yet to be fully elucidated it is thought to involve the down 
regulation of the transcription factor NRF1, which is a known as a positive regulator of mitochondrial 
biogenesis. It was suggested that the expression of KLF2 and ETV1 may be part of a signaling cascade 
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in which lysosomal impairment represses the generation of organelles whose degradation requires the 
functioning of this organelle [26]. 
The putative mechanisms that have been implicated for MRC dysfunction in NPC are outlined in 
Figure 1. 
 
Figure 1. Putative mechanisms responsible for mitochondrial dysfunction in Niemann Pick C. MRC: 
Mitochondrial respiratory chain. ETV1: Transcription factor. KLF2: Transcription factor. OS: Oxidative 
stress. GSH: Reduced glutathione. 
3. LSDs Associated with Nonmembrane-Bound Lysosomal Hydrolases 
3.1. Pompe Disease 
Pompe disease (PD, glycogen storage disease type II) (OMIM #232300) is an autosomal recessive 
condition caused by mutations in the acid-α-glucosidase (GAA) gene. Deficiency of GAA enzyme leads 
to glycogen accumulation and an impairment of autophagy predominantly in skeletal and cardiac 
muscle [27]. 
Lysosomal dysfunction in PD results in incomplete autophagic flux and an accumulation of 
autophagic debris that is particularly prominent in muscle tissue [28,29]. In the absence of the 
disruptive autophagic build-up, recombinant enzyme GAA in enzyme replacement therapy (ERT) is 
able to clear lysosomal glycogen in muscle. The defective autophagy, however, affects trafficking and 
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processing of the ERT [30–33]. Therefore the removal of this autophagic build-up enables efficient 
lysosomal glycogen clearance following ERT [34]. 
It is well documented that muscle pathology in untreated late-onset PD patients, can be 
heterogeneous ranging from the unaffected fibers to severe myopathic changes and considerable 
glycogen accumulation. The variability among PD patients can be explained by the differences in the 
levels of residual enzyme activity. In contrast, the unevenness of fiber involvement in each individual 
patient remains unexplained. Raben et al. [34] demonstrated that autophagic abnormalities are present 
in many muscle cells in late-onset patients (both juvenile and adults) [34]. 
Mitochondrial dysfunction was suggested to be a disease-modifying factor in PD. Fukuda et al. 
[30] reported that mitochondrial dysfunction is present in skeletal muscle pathology and that OS may 
also be associated with PD as indicated by an accumulation of lipofuscin, an autofluorescent material 
composed of oxidatively modified macromolecules detected in the lysosomes, autolysosomes (vesicles 
formed by autophagasomal–lysosomal fusion) and the cytosol of patients and animal models of the 
disease [29]. 
The source of the OS in PD is uncertain as yet. However, impaired mitophagy and disturbed 
calcium signaling may be contributory factors [29]. An impairment of the mitophagic process in PD is 
supported by the accumulation of damaged mitochondria in the cytosol of immortalized murine GAA 
knockout muscle cells (KO cells) [28,35]. The ROS generated by these defective organelles may then 
contribute to cellular OS as indicated in the study by Osellame et al. [7] which reported an association 
between defective mitophagy and cellular OS in a murine model of Gaucher disease.  
An increase in cellular calcium concentration was reported in PD, which is thought to be the result 
of an up-regulation in L-type calcium channel expression. The mechanism inducing this increase in 
calcium channel expression is as yet uncertain, but it may be caused by the limited cellular glucose 
availability impairing the activity of the protein kinase, mammalian target of rapamycin complex 
1(MTORC1) which can then result in an increase in calcium channel gene transcription. However, other 
mechanisms may be responsible for the increase in calcium channel expression [35]. The increase 
cytosolic calcium concentration in PD muscle cells saturates the mitochondria causing a decrease in its 
membrane potential as well as inducing a concomitant rise ROS generation [35]. Studies in murine KO 
muscle cells has indicated that the calcium overloading of the mitochondrion precedes lipofuscin 
accumulation, autophagic build-up and impaired MRC function [29]. 
Evidence of impaired MRC enzyme activities occurred in skeletal muscle tissue from two infants 
with PD. In this study undertaken by Selak et al. [36] the activities of MRC complex I, II, I-III, and II-III 
when expressed as a ratio to citrate synthase (CS) activity, the mitochondrial marker enzyme were 
found to be decreased compared to control levels. Interestingly, there was no evidence of aberrant 
mitochondrial morphology or proliferation to accompany the MRC enzyme deficiencies. Studies by 
Sarnat et al. [37] and Verity [38] have revealed evidence of excessive lipid accumulation in the skeletal 
muscle of PD patients indicating possible evidence of MRC dysfunction. However, no evidence of a 
deficiency in MRC complex II-III or IV activities was reported, although mitochondria were reported 
to have abnormal ultrastructural changes [38].  
The etiology of cardiac complications associated with PD remains to be elucidated since it is 
difficult to obtain cardiac muscle compared with skeletal muscle. However, it has been suggested that 
OS may represent a major mechanistic driver of PD cardiomyopathy as indicated by a decreased 
GSH:GSSG ratio determined in late-onset PD induced pluripotent stem cell derived cardiomyocytes 
[39]. In addition, the antioxidant response element, NF-E2-related factor 2 (NRF-2) was also found to 
be down regulated in cardiomyocytes and skeletal muscle cells derived from a mouse model of PD [39]. 
Morphological studies indicated the presence of larger than normal mitochondria in skeletal 
muscle biopsy derived from a patient with adult onset PD was described by Engel and Dale [40]. These 
mitochondria, which were imperfect oval, polygonal, or prism shaped, contained dense granular 
material and paracrystalline inclusions located in the intercristae space [40–42]. Furthermore, functional 
mitochondria with swollen cristae have been also observed in induced pluripotent stem cells derived 
from the fibroblasts of two patients with PD [43]. 
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Mitochondria were also found in autophagic vacuoles [36] in muscle biopsies of adult PD patients, 
these aberrant mitochondria remain sequestered in the vacuoles and are unable to reach lysosomes for 
recycling. It is still unclear whether mitochondrial abnormalities occur regardless or because of 
impaired autophagy, although calcium dysregulation and cellular OS may also be important 
contributory factor to consider [6]. 
The putative mechanisms that have been implicated for MRC dysfunction in PD are outlined in 
Figure 2 and mitochondrial changes in muscle biopsy from a PD patient is depicted on Figure 3. 
Mitochondrial changes in her muscles continued to be present despite ongoing ERT. 
 
Figure 2. The putative mechanisms that have been implicated in inducing mitochondrial dysfunction in 
Pompe disease. MRC: Mitochondrial respiratory chain. Ca2+: Calcium. MTORC1: mammalian target of 
rapamycin complex 1. ROS: Reactive oxygen species. 
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Figure 3. the muscle biopsy from a patient with late-onset Pompe disease (PD) shows myopathic 
changes including atrophic and hypertrophic fibers; one fiber with subsarcolemmal accumulation of 
mitochondria is also present (asterisk). (A)—hematoxylin-eosin, ×20; staining for acid phosphatase 
highlights the increase in lysosomes in muscle fibers. (B)—acid phosphatase, ×20; several COX-negative 
fibers (blue) are documented in the combined staining COX/SDH. (C)—COX/SDH, ×20. 
3.2. Mucopolysaccharidosis 
Mucopolysaccharidosis (MPS; type I, II, III, IV, VI, VII) are disorders affecting the enzymes needed 
for the stepwise degradation of glycosaminoglycans (GAGs). The pathophysiology of MPS has not yet 
been fully elucidated, although, inflammation, oxidative stress (OS) and mitochondrial dysfunction are 
thought to be important contributory factors to the disease progression. A study utilizing a mouse 
model of MPS IIIC (OMIM # 252930) provided insights into the disease mechanisms of MPS yielding 
evidence that may link neuroinflammation, mitochondrial dysfunction and neurodegeneration [44]. 
MPS IIIC is a severe neurologic disease caused by a genetic deficiency of heparan sulphate (HS) acetyl-
CoA: a-glucosaminide N-acetyltransferase (HGSNAT) [44,45]. The result of the study indicated that HS 
and HS-derived oligosaccharide accumulating in the microglial cells may be the primary pathological 
event that triggers a cascade of reactions that eventually result in neuronal loss [44]. The HS and HS-
derived oligosaccharides stored in the lysosomes of the microglia as well as the neurons to a lesser 
degree once released from the cells by exocytosis are then thought to induce a spectrum of 
inflammatory reactions in the brain by activation of the Toll-like receptors (TLR) present on the 
microglia [44,46]. The activation of the TLR receptors are then thought to induce the release of pro-
inflammatory cytokines, MIP1a and TFN which were detected in brain tissue from the mouse model of 
MPS IIIC [44]. In addition, activated microglia also release ROS and reactive nitrogen species (RNS) 
including nitric oxide (NO) and peroxynitrite [47,48]. TFN induction of astrocytic inducible NO 
synthase activity may also be another source of RNS since activated astrocytes were detected 
throughout the brain of the mouse model of MPS IIIC [45,49]. The exposure of the neurons to the 
extracellular RNS and ROS may then have contributed to the progressive neuronal mitochondrial 
dysfunction reported in the animal model [44]. Evidence of neuronal mitochondrial impairment in this 
model was indicated by the presence of pleotropic and swollen mitochondria which were increased in 
number with many of them being swollen and containing disorganized cristae [44]. A study by Doll et 
al. [50] utilizing immortalized mouse hippocampal cells has indicated that MRC impairment may be 
caused by direct exposure to TFN irrespective of the mitochondrial toxicity induced by ROS and RNS. 
Although, its mechanism of action is uncertain, the loss of mitochondrial membrane potential 
associated with TFN treatment indicates the ability of this cytokine to induce a disruption of the 
structural integrity of the mitochondrial membranes [50]. Commensurate with its potential 
mitochondrial toxicity, TFN treatment is also associated with an increase in mitochondrial ROS 
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generation [51]. The exposure of neurons to both external and internal sources of OS may explain the 
progressive mitochondrial dysfunction reported in the mouse model of MPS IIIC, which was also 
accompanied by a reduction in neuronal density [44]. In addition to morphological abnormalities, 
potential mitochondrial dysfunction in MPS IIIC has been indicated by the decreased MRC complex II 
and IV activities detected in brain mitochondria isolated from the MPS IIIC mouse model at the latter 
stages of the disease which was accompanied by a deficit in cerebral CoQ10 status [44,45]. 
Interestingly, a deficit in plasma CoQ10 status was also reported in MPS patients, including those 
with MPS IIIC [11]. It was proposed that the reduction in circulatory CoQ10 status may be related to 
the low level of vitamin B6 detected in the patients. The active form of vitamin B6, pyridoxal 5-
phosphate, is required for the transamination of tyrosine into 4-hydroxyphenylpyruvic acid, an 
essential step in CoQ10 biosynthesis [11]. GAGs which are known to accumulate in MPS disorders may 
bind vitamin B6 reducing its circulatory levels [11]. The cause of the cerebral CoQ10 deficiency reported 
in the MPS IIIC mouse is as yet uncertain; however, it may be associated with the evidence of OS 
reported in MPS patients and animal model of the disease [52]. A study by Trudel et al. [53] using a 
mouse model of MPS IIIB (OMIN #252920) suggested that cerebral OS associated with this disorder 
may not be a secondary consequence of neuroinflammation but rather as a direct result of cellular HS 
accumulation, although, the mechanism(s) has yet to be elucidated.  
An impairment of neuronal autophagosome–lysosome fusion and consequently, mitophagy was 
indicated in the mouse model of MPS IIIC which would account for the progressive accumulation of 
gangliosides, subunit c of mitochondrial ATP synthase (SCMAS) aggregates and deformed and 
dysfunctional mitochondria which have been detected in the advanced stages of the disease [44]. It was 
suggested that GAG accumulation impairs the lysosomal functions required to support autophagic 
degradation, although the mechanism(s) has yet to be fully elucidated [54]. The accumulation of 
dysfunctional mitochondria as a consequence of impaired mitophagy would also be expected to be a 
source of ROS generation contributing to neuronal OS [55]. 
Another MPS disorder, Maroteaux–Lamy syndrome (MPS VI), is caused by a deficiency of the 
lysosomal enzyme N-acetylgalactosamine-4-sulfatase [54]. It has been demonstrated that excessive 
dermatan sulphate accumulation alters the lysosomal ability to degrade cytoplasmic components or 
organelles through autophagy. Lysosomal storage leads to reduced functionality of lysosomes and 
consequently, autophagy deregulation [56]. Tessitore et al. [54] have shown evidence of impaired 
autophagy with increased levels of autophagic proteins, increased polyubiquitination and an 
accumulation of aberrant mitochondria within the autophagic vacuoles in human MPS VI fibroblasts 
as well as in affected tissues of an MPS VI rodent model. In vivo, this was associated with inflammation 
and apoptosis. Abnormal autophagy was described in other LSDs, proving that common mechanisms 
are downstream of different genetic defects in LSDs, including Mucolipidosis type II and IV (Table 1). 
The impairment in autophagy resulting in an accumulation of aberrant mitochondria would be 
expected to cause an increase in cellular ROS generation and concomitant cellular dysfunction as has 
been suggested for MPS III C [54]. 
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Table 1. Mitochondrial dysfunction in lysosomal storage diseases. 
Disorder Enzyme Deficient/Protein Affected 
Genetic 
Defect 
Storage Material/Pathologic 
Hallmark 
Domain of Mitochondrial Dysfunction References  
Lysosomal Storage Disorders (LSDs) Associated with Integral Lysosomal Membrane Proteins 
Niemann Pick C 
Glycosylated transmembrane protein of 
the lysosomal membrane 
NPC1 and 
NPC2 
gene 
Intracellular accumulation of 
cholesterol and other lipids like 
glycosphingolipids, 
sphingomyelin and sphingosine 
in the lysosomes and late 
endosomes 
Autophagosomes accumulation and 
autophagy dysfunction in disease 
pathogenesis. 
[57–59] 
Induction of autophagy. 
Lysosomal cholesterol and lipid export, foam 
cells in visceral organs and neuronal storage. 
Mucolipidosis IV TRPML-I (ion channel- mucolipin 1) 
MCOLN1 
gene 
Lipofuscin in lysosomes, lipids  
Autophagosomes accumulation and 
authophagy dysfunction in disease 
pathogenesis.  [57,60–63] 
Block of authophagosome-lysosome 
maturation.  
Cystinosis 
Reduced or absent function of the specific 
carrier cystinosin 
CTNS 
gene 
Cystine in lysosomes 
Mitochondrial fusion is mediated by three key 
regulatory fusion proteins: the dynamin-
related GTPases mitofusin 1 (MFN1) and 
mitofusin 2 (MFN2), and the dynamin-related 
GTPases optic atrophy 1 (OPA1); altered 
endosomal trafficking, impaired autophagy, 
and cell oxidation 
[64,65] 
Danon disease LAMP-2 lysosomal membrane protein 
LAMP-2 
gene 
Glycogen 
Autophagic flux, which results in excessive 
oxidative stress, and subsequent 
[57,66,67] 
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cardiomyocyte apoptosis; autophagosome 
accumulation, autophagy dysfunction in 
disease pathogenesis, block of 
autophagosome–lysosome maturation. 
LSDs Associated with Nonmembrane-Bound Lysosomal Hydrolases 
Pompe alpha-Glucosidase GAA gene Glycogen  
Autophagosomes accumulation and 
autophagy dysfunction in disease 
pathogenesis;  [30,57,59] 
(Autophagic) accumulation in type II muscle 
fibers 
Mucopolysaccharidosis: 
III A 
heparan N-sulfatase  SGSH 
gene 
Heparan sulphate  
Autophagosomes accumulation,  
[44,56,57,68,69] 
N-acetyl-alpha-D-glucosaminidase  
IIIB 
acetyl-CoA:aglucosaminide 
acetyltransferase  
NAGLU 
gene 
autophagy dysfunction in disease 
pathogenesis,  
block of autophagosome–lysosome 
maturation;  
N-acetylglucosamine-6-sulfate sulfatase  IIIC 
HGSNAT 
gene 
Accumulation, Fragmentation/swelling, 
Selective reduction of OXPHOS complexes,  
IIID GNS gene Decreased coenzyme Q10 
Mucopolysaccharidosis 
VI (Maroteaux–Lamy) 
N-acetylgalactosamine-4-sulfatase 
ARSB 
gene 
Dermatan sulphate  
Autophagosome–lysosome fusion is not 
completely blocked; accumulation of 
dysfunctional mitochondria; increased levels 
of autophagic proteins, increased 
polyubiquitination and abnormal 
mitochondrial function 
[54] 
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Multiple Sulphatase 
Deficiency 
Sulphate esters (At least 7 lysosomal 
sulfatases and a microsomal sulfatase) 
SUMF1 
gene 
- 
Autophagosomes accumulation, autophagy 
dysfunction in disease pathogenesis, induction 
of autophagy. Accumulation, Fragmentation, 
Decreased ATP content 
[56,57,68,70] 
Mucolipidoses II 
N acetylglucosaminylphosphotransferase 
resulting in multiple enzyme deficiencies 
GNPTAB 
gene 
Mucopolysaccharides, lipids, 
glycoproteins 
Autophagic and mitochondrial impairment. [71–73] 
Mucolipidosis III 
Dysfunctional autophagosome, vacuolization 
(accumulation of autolysosomes)  
[74] 
Gangliosidosis: 
GM1 
beta-galactosidase 
GLB1 
gene 
Gangiosides  
Autophagosomes accumulation, autophagy 
dysfunction is disease pathogenesis, induction 
of autophagy. 
[57,75,76] 
GM2 beta-hexosaminidase 
HEXB 
gene 
Fabry disease alpha-galactosidase A  GLA gene globotriasylceramide (Gb3) 
Increased vacuoles level, reduction of 
mitochondrial activity, Lipid storage in 
endothelial and smooth muscle cells of blood 
vessels 
[59,77] 
Farber disease Ceramidase 
ASAH1 
gene 
Ceramides, 
mucopolysaccharides, 
gangliosides 
Ceremide/cholesterol structures accumulate in 
late endosomes and lysosomes, in 
mitochondria and the plasma membrane 
[78] 
Gaucher disease glucocerebrosidase (GBA1) 
GBA1 
gene 
Glycosphingolipids, 
Glucosylceramide, GM1, GM2, 
GM3, GD3, Glucosylsphingosine 
Impaired autophagy and proteasomal 
degradation pathways and mitochondrial 
dysfunction; pathological [Ca2+]c responses 
and delayed calcium deregulation, collapse of 
mitochondrial membrane potential and an 
irreversible fall in the ATP/ADP ratio; lipid 
storing macrophages 
[8,79–83] 
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Krabbe disease Galactosylceramidase 
GALC 
gene 
galactosyl-ceramide and 
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(psychosine) 
Mitochondrial morphology ad accumulation,  
[68,84,85] 
calcium signaling, oxidative stress and 
macromolecules accumulation in 
mitochondria; 
Elevated ROS/reduced GSH,  
Ca2+ overload,  
Cytochrome c release 
LSDs Associated with Other Defects 
Neuronal Ceroid 
Lipofuscinosis (Batten’s 
disease) 
Lysosome protease deficiencies 
CLN1–
CLN12 
gene 
Lipofuscin  
Active regulation of ATP synthase by Ca2+ is 
maintained in fibroblasts from CLN 2 and 
CLN3 but absent in those from CLN1. 
Autophagosome accumulation, autophagy 
dysfunction in disease pathogenesis, induction 
of authophagy. 
[57,68,86–88] 
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The putative mechanisms that have been implicated for MRC dysfunction in MPS according to 
studies in patients and animal and cell models of the disease are outlined in Figure 4. 
 
Figure 4. Putative mechanisms responsible for mitochondrial dysfunction in Mucopolysaccharidosis. 
HS: Heparin sulphate. MRC: Mitochondrial respiratory chain. ROS: Reactive oxygen species. RNS: 
Reactive nitrogen species. TNF: Cytokine. 
3.3. Fabry Disease 
Fabry Disease (FD) (OMIM #300644) is an X-linked lysosomal storage disorder caused by the 
deficiency of the enzyme alpha-galactosidase A. It results in progressive intracellular deposition of 
globotriaosylceramide (GB3) and related neutral glycosphingolipids in multiple organ systems, 
including skin, kidneys, vascular endothelium, ganglion cells of the peripheral nervous system, and 
heart [89]. 
Several studies suggested that OS may be implicated in the pathophysiology of FD, particularly 
the cardiovascular involvement of the disease. GB3 accumulation was reported to cause a dose 
dependent increase in ROS production in cultured vascular endothelial cells from FD patients [90]. 
Interestingly, culturing endothelial cells in plasma from FD patients significantly increased ROS 
generation when compared with plasma from non-FD controls, although this effect was not found to 
be dependent upon GB3 levels suggesting that other factors in the plasma may also be responsible 
for inducing OS [90]. A subsequent study by Biancini et al. [91] reported evidence of OS and 
inflammation in the plasma of FD patients receiving ERT as indicated by markers of lipid and protein 
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oxidation together with the pro-inflammatory cytokines, IL-6 and TNF. Furthermore, erythrocyte 
GSH status was found to be decreased in the FD patients together with a reduction in glutathione 
peroxidase activity and an elevated superoxide dismutase (SOD): catalase activity ratio [91]. The 
authors speculated that this altered SOD: catalase activity ratio may lead to an increased availability 
of the ROS, hydrogen peroxide. Urinary GB3 was found to be correlated with the plasma markers of 
both OS and inflammation which indicates an association between GB3 and the pro-oxidant and pro-
inflammatory states of FD [91]. An accumulation of circulatory levels of GB3 and its deacetylated 
form, lyso-GB3 are thought to induce inflammation by binding to and activating the TLR receptors 
of the dendritic cells and as a consequence cause the generation of ROS and RNS [92]. A study by 
Tseng et al. [93] reported that the protein level of the mitochondrial antioxidant enzyme, SOD-2 was 
down regulated in FD-specific human induced pluripotent stem cells which was found to be 
associated with an increase in ROS generation together with an enhanced cellular accumulation of 
GB3. 
GB3 treatment of human microvascular cardiac endothelial cells was reported to decrease the 
expression of NO synthase (eNOS), whereas, the expression of inducible NO synthase (iNOS) was 
found to be increased [94]. Moreover, alpha-galactosidase A deficiency has been associated with 
increased nitrotyrosine (a marker of reactive nitrogen species, RNS production) expression in aortic 
endothelial cells isolated from a mouse model of the disease [95]. Increased nitrotyrosine levels were 
also detected in skin biopsies and brain tissue from FD patients [96,97]. More recently, Shu et al. [98] 
demonstrate that alpha-galactosidase A knockdown by RNA interference in a human endothelial cell 
line results in GB3 accumulation, reduced endothelial NO synthase activity, and dramatically 
enhanced nitrotyrosine production. In addition, elevated levels of nitrotyrosine were detected in the 
plasma and aortic tissue of a alpha-galactosidase A knockout mouse, as well as in the plasma of 
untreated male patients with FD [98]. GB3 was reported to be widely distributed in the cell and be 
present in other organelles such as the nucleus and endoplasmic reticulum rather than being confined 
to the lysosome [99]. The presence of GB3 in the nucleus may be an explanation for its ability to induce 
iNOS whilst inhibiting the expression of eNOS [94]. iNOS produces large amounts of NO in 
comparison to eNOS, which is highly reactive with other free radicals. NO reacts with superoxide to 
form peroxynitrite, and this RNS can induce oxidative damage to biomolecules as well as the nitration 
of proteins explaining the high level of nitrotyrosine detected in FD patients as well as animal and 
cell models of the disease [100]. The loss of eNOS activity in FD disease which is essential for the 
maintenance of vascular homeostasis may contribute to the risk of incipient vasculopathy and 
provide a pathologic milieu for the accelerated development of cardiovascular complications 
associated with this disorder [94]. Therefore, nitrotyrosine represents a potential biomarker for 
vasculopathy in FD as well as indicating evidence of RNS generation [98]. GB3 induced ROS and 
RNS production was reported to contribute to cardiac dysfunction as well as promote cardiomyocyte 
protein nitration and DNA damage in FD [97]. 
In addition to oxidative and nitrosative stress as well as inflammation, evidence of MRC 
dysfunction was reported in FD. Lücke et al. [101] reported decreased MRC complex II, IV, and V 
activities in fibroblasts from FD patients compared to controls. The molecular mechanism responsible 
for the loss of MRC enzyme activity was not investigated in the study by Lücke et al. [101] and the 
accumulation of lysosomal storage (GB3) material may have caused the mitochondrial dysfunction. 
However, the possibility arises that the elevated levels of ROS and RNS associated with FD may have 
also contributed to the MRC impairment in view of their ability to cause oxidative damage to 
mitochondrial proteins, lipid and DNA [42]. In vivo studies were also documented impaired 
oxidative phosphorylation as indicated by the decreased level of the high energy phosphate 
molecules, ATP and creatine phosphate detected in the heart of FD patients [102]. Subsequent ERT 
was reported to result in a partial restoration in the cardiac level of these molecules.  
Variation in mitochondrial DNA (mtDNA) haploid groups amongst FD patients may account 
for the differences in the susceptibility of individuals to ROS induced mitochondrial dysfunction as 
well as the ability of MRC to generate sufficient ATP via oxidative phosphorylation during cellular 
morbidity [103]. The susceptibility of mitochondria and mtDNA to OS induced dysfunction OS may 
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also vary between tissues, thus modulating the phenotype and the natural course of the disease. 
Although certain haploid groups were shown to be more prevalent in patients, there was no observed 
correlation with gender, age of onset, or organ involvement [104]. 
The impaired mitochondrial energy supply in skin fibroblasts from a patient with FD is depicted 
on Figure 5. Compromised mitochondrial function may play a role in the pathogenesis of FD and is 
present despite of ERT (Figure 5). Fatigue and myopathy may be attributed to mitochondrial changes 
rather than FD itself. A trial of CoQ10 has been recommended with a variable outcome (KMS: 
personal observation). 
The putative mechanisms that have been implicated for OS and MRC dysfunction in FD are 
outlined in Figure 6.  
 
Figure 5. these images document the muscle from a patient with Fabry’s disease on ERT treatment; 
the biopsy is characterized by abnormal variation in fibre size and a few fibres showing internal 
nucleation (A, hematoxylin-eosin, x20); focal subsarcolemmal accumulation of mitochondria but no 
ragged red fibres is seen (arrow) (B – modified Gomori’s trichrome, x40); a COX-negative fibre is 
present (blue fibre, arrow) (C – COX/SDH staining, x40); there is increase staining with acid 
phosphatase (red precipitate) that due to subsarcolemmal deposits of lipofuscins and increase in 
lysosomes (D – acid phosphatase, x20). 
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Figure 6. Putative causes of mitochondrial dysfunction in Fabry disease. GB3: globotriaosylceramide. 
Lacg: Lacoglyceramide. α-galA: alpha-galactosidase A. SOD-2: Superoxide dismutase-2. 
eNOS:endothelial nitric oxide synthase. iNOS: inducible nitric oxide synthase. MRC: Mitochondrial 
respiratory chain. GSH: Reduced glutathione. ROS: Reactive oxygen species. RNS: Reactive oxygen 
species. NO: Nitric oxide. 
4. Discussion 
Mitochondrial dysfunction is emerging as an important contributory factor in the 
pathophysiology of LSDs. It is unsurprising given the symbiotic relationship between the two 
organelles although the molecular mechanisms governing this co-operation have yet to be fully 
elucidated. The impairment of lysosomal function in LSDs can directly impact upon the 
mitochondrion by perturbation of mitophagy [7]. The accumulation of mitochondria with impaired 
MRC function, as has been reported in LSDs, can cause an increased generation of cellular ROS and 
result in oxidative damage to the organelles including the lysosome as well as further impair 
mitochondrial function since the MRC is very vulnerable to OS induced inactivation. In addition to 
OS, which has been widely reported in LSDs and from sources other than the mitochondria, MRC 
dysfunction may also be caused from inhibition by macromolecules and protein aggregates which 
accumulate in the cytosol as a consequence of impaired autophagy [7]. Furthermore, MRC 
dysfunction in LSDs may also result from the alteration in lipids of the inner mitochondrial 
membrane (e.g., in NPC1) [21] or as the result of defects in calcium homeostasis (e.g., in PD) [105]. 
MRC dysfunction in LSDs, will eventually deprive the cell of ATP, which apart from being essential 
for maintaining lysosomal acidity will also cause cellular morbidity. Therefore, given the profound 
mitochondrial dysfunction that has been reported in some LSDs [68], treatment strategies that target 
the mitochondria may prove to be of therapeutic benefit to patients. Therefore, in view of the 
susceptibility of the MRC to OS induced impairment, a number of studies on antioxidant treatment 
have been undertaken employing both patient cells and animal models of LSDs. It is unknown 
however whether a similar response would be observed in clinical trials. It is known that even for 
primary mitochondrial diseases in which a CoQ10 deficiency is demonstrated in vitro, oral 
supplementation does not yield attainable clinical response for those patients. 
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A study utilizing Gaucher disease patient fibroblasts reported that combined pharmacological 
chaperone therapy with CoQ10 treatment was able to increase glucocerebrosidase activity and 
improve mitochondrial function [106]. Currently, there is a clinical trial to assess the therapeutic 
efficacy of N-acetyl cysteine (trial NCT03759639), the GSH precursor in NPC which is running at the 
National Institute of Health Clinical Centre in USA (https://www.mayo.edu/research/clinical-
trials/cls-20467313), although there is no indication when the results will be available.  
Matalonga et al. [107] reported that treatment with both CoQ10 and antioxidant cocktail (α-
tocopherol, N-acetylcysteine and α-lipoic acid) was able to significantly decrease GAG accumulation 
in selected MPS III patient fibroblasts. Apart from CoQ10, other products were investigated in MPS 
disorders. Genistein, a natural isoflavone, was considered an autophagy stimulator in experimental 
studies [108]. Trehalose, another autophagy stimulator, was shown to improve symptoms in MPS 
IIIB mice [109]. It was, therefore, postulated that autophagy can be profitable at least for animals 
affected with MPS as shown in vitro studies [110]. Strategies that enhance autophagy may provide 
judicious in the treatment of LSD as well as utilizing treatments that maximize residual MRC 
activities [10,79]. The enhancement of TFEB (master gene for that regulates lysosomal biogenesis) 
expression may prove beneficial to LSD patients since this has the potential to enhance mitophagy 
by maintenance of autophagy-lysosome pathway in addition to its ability to also induce 
mitochondrial biogenesis [110,79]. However, since multiple cellular pathways are impaired in LSDs, 
therapeutic strategies to ameliorate OS, improve mitochondrial function, and enhance autophagy 
combined with ERT may prove beneficial in the treatment of these disorders. Some other therapeutic 
approaches that target OS or mitigate mitochondrial dysfunction are available. One of these 
compounds is the CoQ10 analogue, idebenone, which as well as functioning as an antioxidant is able 
to mediate electron flow from the cytosol to complex III of the MRC and therefore bypass an MRC 
complex I deficiency [111]. Another compound to consider is the synthetic quinone, EPI-743 which 
has been reported to replenish GSH levels in both cell and human studies [111]. Thiamine (vitamin 
B1) may also be appropriate to increase the activity of pyruvate dehydrogenase, and thus enhance 
the oxidase decomposition of pyruvate [87]. Elamipretide is an aromatic cationic tetrapeptide, which 
has been reported to selectively bind to cardiolipin, a phospholipid component of the inner 
mitochondrial membrane which is required for optimal MRC activity and is able to protect it from 
oxidative damage [87]. Elamipretide inhibits the opening of mitochondrial permeability transition 
pore and enhances MRC function and is now used as a drug for the treatment of primary 
mitochondrial myopathy [87]. However, the use of appropriate markers to indicate evidence of 
mitochondrial function and OS as well as to monitor therapeutic intervention in LSDs will also prove 
to be of similar importance. 
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